Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism [PDF]
Frontiers in Pharmacology, 2023 Many drugs have been shown to be metabolized by the human gut microbiome, but probiotic-driven drug-metabolizing capacity is rarely explored. Here, we developed an integrated metabolomics, culturomics, and bionics framework for systematically studying ...
Bohai Li +17 more
doaj +5 more sources
Racecadotril for acute diarrhoea in children [PDF]
Cochrane Database of Systematic Reviews, 2019 Acute diarrhoea is a leading cause of death for children under five years of age. Most deaths are caused by excessive fluid and electrolyte losses. Racecadotril is an anti-secretory drug that has been used for acute diarrhoea in children as an adjunct to oral rehydration therapy.To assess the efficacy and safety of racecadotril for treating acute ...
Liang, Yi +4 more
europepmc +7 more sources
Randomized trial to assess the efficacy and safety of xyloglucan for the treatment of acute gastroenteritis in children [PDF]
Food Science &Nutrition, Volume 11, Issue 12, Page 7698-7706, December 2023., 2023 Xyloglucan is effective and safe in moderate‐to‐severe diarrhea in children 3 months to 5 years. Abstract Acute gastroenteritis is one of the most common diseases in children and an important cause of morbidity and mortality worldwide. No specific treatment is available; therefore, management is exclusively symptomatic.
Maria Jose Perez‐Garcia +17 more
wiley +2 more sources
Research in Pharmaceutical Sciences, 2021 Background and purpose: Although pain is one of the most common symptoms of diseases, it is often mismanaged due to limited access to painkillers and ineffectiveness, unacceptable side effects, or the possibility of abuse.
Mehdi Asadi +5 more
doaj +2 more sources
A comprehensive review of the pharmacodynamics, pharmacokinetics and clinical effects of the neutral endopeptidase inhibitor racecadotril [PDF]
Frontiers in Pharmacology, 2012 Racecadotril, via its active metabolite thiorphan, is an inhibitor of the enzyme neutral endopeptidase (NEP, EC 3.4.24.11), thereby increasing exposure to NEP including enkephalins and atrial natriuretic peptide.
Marion eEberlin +2 more
doaj +5 more sources
Understanding the Anti-Diarrhoeal Properties of Incomptines A and B: Antibacterial Activity against Vibrio cholerae and Its Enterotoxin Inhibition [PDF]
Pharmaceuticals, 2022 Incomptines A (IA) and B (IB) are two sesquiterpene lactones with antiprotozoal, antibacterial, cytotoxic, antitumor, spermicidal, and phytotoxic properties.
Fernando Calzada +7 more
doaj +2 more sources
Racecadotril for acute diarrhoea in children: systematic review and meta-analyses [PDF]
Archives of Disease in Childhood, 2015 ObjectiveRacecadotril is an antisecretory agent that can prevent fluid/electrolyte depletion from the bowel as a result of acute diarrhoea without affecting intestinal motility. An up-to-date systematic review is indicated to summarise the evidence on racecadotril for the treatment of acute diarrhoea in children.DesignA Cochrane format systematic ...
Gordon, Morris, Akobeng, Anthony
openaire +5 more sources
Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. [PDF]
Br J Pharmacol, 2019 This is the peer reviewed version of the following article: Hobbs AJ, Moyes AJ, Baliga RS, et al. Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial. Br J Pharmacol.
Hobbs AJ +14 more
europepmc +3 more sources
Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials [PDF]
BMC Pediatrics, 2018 Background Racecadotril is a guideline-recommended option for the treatment of acute diarrhea in children but existing guidelines and previous reviews of the field are based on a small fraction of published evidence.
Marion Eberlin +3 more
doaj +2 more sources
Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study [PDF]
The Journal of Dermatology, Volume 52, Issue 6, Page 1059-1065, June 2025.ABSTRACT Apremilast is a phosphodiesterase 4 inhibitor approved for moderate to severe psoriasis in Japan. Apremilast significantly improved Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) both at 6 and 12 months in a previously published primary post‐surveillance study.
Mamitaro Ohtsuki +8 more
wiley +2 more sources